[1]张晓欲*,左金玲,谷丽,等.miR-200 a联合糖类抗原125、白介素-17检测在上皮性卵巢癌早期诊断中的价值[J].中国计划生育和妇产科,2020,(1):64-68.
　ZHANG Xiao-yu*,ZUO Jin-ling,GU Li,et al.The value of detection of microRNA-200 a combined with CA 125 andIL-17 in early diagnosis of epithelial ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2020,(1):64-68.
点击复制

miR-200 a联合糖类抗原125、白介素-17检测在上皮性卵巢癌早期诊断中的价值
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2020年1期
页码:
64-68
栏目:
论著与临床
出版日期:
2020-01-25

文章信息/Info

Title:
The value of detection of microRNA-200 a combined with CA 125 and IL-17 in early diagnosis of epithelial ovarian cancer
作者:
张晓欲1*; 左金玲2; 谷丽1; 宋志慧2; 董娜1
唐山市妇幼保健院，1.妇科；2.产科
Author(s):
ZHANG Xiao-yu1*; ZUO Jin-ling2; GU Li1; SONG Zhi-hui2; DONG Na1
1.Department of Gynecology; 2.Department of Obstetrics,Maternal and Child Health Hospital of Tangshan,Tangshan Hebei 063000,P.R.China
关键词:
上皮性卵巢癌; 诊断; miR-200 a; 糖类抗原125; 白介素17
Keywords:
epithelial ovarian cancer;  diagnosis;  miR-200a;  carbohydrate antigen 125;  interleukin 17
分类号:
R 737.31
摘要:
目的探讨血浆miR-200 a、糖类抗原125（carbohydrate antigen 125，CA 125）、白介素-17（interleukin-17，IL-17）联合检测在早期上皮性卵巢癌中的诊断价值。方法选取2015年8月至2018年8月唐山市妇幼保健院收治的卵巢肿瘤患者128例为研究对象，其中上皮性卵巢癌59例，卵巢良性肿瘤69例，选取同期体检健康者74例为对照组，比较3组受试者血浆miR-200 a、CA 125、IL-17水平差异，并分析3者与上皮性卵巢癌临床病理组织类型及临床分期关系，应用受试者工作曲线（receiver operating characteristic curve, ROC）分析血清miR-200 a、CA 125、IL-17水平以及3者联合对上皮性卵巢癌的诊断价值。结果上皮性卵巢癌组血浆miR-200 a、CA 125、IL-17水平高于卵巢良性肿瘤组与对照组，差异均有统计学意义（P＜005）；卵巢良性肿瘤组与对照组比较差异无统计学意义（P＞005）。与中、高分化、TNM分期I期相比，低分化、TNM分期II期患者血浆miR-200 a、CA 125、IL-17表达显著升高（P＜005）；ROC曲线显示，血浆miR-200 a、CA 125、IL-17及3者联合检测预测早期上皮性卵巢癌的曲线下面积分别为0793（敏感度为831 %，特异性为826 %）、0820（敏感度为897 %，特异性为7100 %）、0889（敏感度为915 %，特异性为797 %）、0943（敏感度为949 %，特异性为841 %）。结论上皮性卵巢癌患者血浆miR-200 a、CA 125、IL-17水平升高，3者联合检测可能作为上皮性卵巢癌的早期诊断指标。
Abstract:
ObjectiveTo investigate the diagnostic value of combined detection of plasma miR-200 a, carbohydrate antigen 125 (CA 125) and interleukin 17 (IL-17) in early epithelial ovarian cancer. Methods128 patients with ovarian tumors admitted in Maternal and Child Health Hospital of Tangshan from August 2015 to August 2018 were selected, including 59 cases of epithelial ovarian cancer and 69 cases of benign ovarian tumors. Another 74 healthy persons were selected as the control group during the same period. The levels of plasma miR-200 a, CA 125 and IL-17 were compared among the three groups, and their relationship with the clinical pathological types and clinical stages of epithelial ovarian cancer were analyzed, the diagnostic values of Serum levels of miR-200 a, CA125, IL-17 and their combination for epithelial ovarian cancer were analyzed by receiver operating curve (ROC). ResultsThe levels of plasma miR-200 a, CA 125, and IL-17 in the epithelial ovarian cancer group were higher than those in the benign ovarian tumor group and the control group, and the differences were statistically significant (P<005). There was no significant difference between the benign ovarian tumor group and the control group (P>005).Compared with moderately, highly differentiated, and TNM stage I, plasma miR-200 a, CA 125, and IL-17 expressions in patients with low differentiated and TNM stage II were significantly increased (P<005); The ROC curve showed that the areas under the curve for the prediction of early epithelial ovarian cancer by combined detection of plasma miR-200 a, CA 125, IL-17 and 3 were 0793 (sensitivity 831 %, specificity 826 %), 0820 ( Sensitivity is 897 %, specificity is 7100 %), 0889 (sensitivity is 915 %, specificity is 797 %), 0943 (sensitivity is 949 %, specificity is 841 %). ConclusionPatients with epithelial ovarian cancer have elevated levels of miR-200 a, CA 125, and IL-17. The combined detection of these three may be used as an early diagnostic indicator of epithelial ovarian cancer.

参考文献/References:

［1］彭琼, 朱碧琳血清人附睾分泌蛋白-4对上皮性卵巢癌的早期诊断价值研究［J］中国实验诊断学, 2018, 22(4):628-629 ［2］于华实, 李昊, 杜慧雪,等基于功能组学数据识别卵巢癌风险microRNA ［J］. 中国肿瘤临床与康复, 2017, 24(6):673-676. ［3］萨伊普加玛丽·米吉提, 艾迪拜·木合买提, 苏比努尔·买买提,等. HE4联合CA125及彩色多普勒超声在上皮性卵巢癌诊断中的价值 ［J］. 中国妇幼保健, 2017, 32(6):1324-1327. ［4］陈献, 张晓洁, 尚文雯,等. IL-17A在卵巢癌组织中的表达及临床意义 ［J］. 免疫学杂志, 2018, 34(6):529-533. ［5］Oza A M, Cibula D, Benzaquen A O, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial［J］. Lancet Oncol, 2015, 16(1):87-97. ［6］Sureban S M, May R, Lightfoot S A, et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanis［J］. Cancer Res, 2015, 71(6):2328-2338. ［7］Sánchez-Cid L, Pons M, Lozano J J, et al. MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells［J］. Oncotarget., 2017, 8(48):83384-83406. ［8］Pendlebury A, Hannan N J, Binder N, et al. The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer［J］. Biomed Rep, 2017, 6(3):319-322. ［9］Pan Q, Meng L, Ye J, et al. Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT)［J］. Cancer Lett, 2017, 392(1):26-38. ［10］吕晓兰, 康媛媛. 上皮性卵巢癌术前血清CA125水平与临床病理特征及患者预后的关系 ［J］. 海南医学, 2017, 28(22):3664-3666. ［11］Guo J, Yu J, Song X, et al. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A Metaanalysis ［J］. Open Med, 2017, 12(1):131-137. ［12］Xiong H, Wei L, Peng B. IL‐17 stimulates the production of the inflammatory chemokines IL‐6 and IL‐8 in human dental pulp fibroblasts ［J］. Int Endod J, 2015, 48(6):505-511. ［13］Herjan T, Hong L, Bubenik J, et al. IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling ［J］. Nat Immunol, 2018, 19(4):354-365. ［14］宋静静, 单保恩, 王浩. 外源性IL-17对胃癌细胞生物学特性的影响及其机制研究［J］. 中国肿瘤, 2018, 27(11):867-873. ［15］朱攀, 马瑞, 雷蜜. 上皮性卵巢癌患者中血清CA125、HE4、SMRP及细胞因子IL-8、IL-17联合检测意义分析 ［J］. 海南医学院学报, 2017, 23(8):1120-1123. ［16］熊雯, 周新娥, 黄娟,等. 血清CA125、HE4及IL-17检测对上皮性卵巢癌的早期诊断价值分析 ［J］. 中国计划生育和妇产科, 2016, 8(3):69-73.

相似文献/References:

[1]李桂兰.青春期子宫内膜异位症的诊治进展[J].中国计划生育和妇产科,2010,(03):0.
[2]刘彩艳.宫角妊娠34例诊治分析[J].中国计划生育和妇产科,2010,(04):0.
[3]何博.妊娠合并先天性心脏病的诊治研究进展[J].中国计划生育和妇产科,2010,(04):0.
[4]卢庆.妊娠期急性脂肪肝研究进展[J].中国计划生育和妇产科,2010,(05):0.
[5]张理琼,汤蓓,廖林,等.产前超声诊断胎儿先天性肺囊腺瘤畸形[J].中国计划生育和妇产科,2010,(06):0.
　ZHANG Li-qiong,TANG Bei,LIAO Lin.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(1):0.
[6]宋萌颖,张秋生.T形节育器异位至输卵管1例[J].中国计划生育和妇产科,2010,(06):0.
[7]张理琼,黄欣,廖林,等.产前超声诊断完全型胎儿房室间隔缺损的价值[J].中国计划生育和妇产科,2011,(02):0.
　ZHANG Li-qiong,HUANG Xin,LIAO Lin..[J].Chinese Journal of Family Planning & Gynecotokology,2011,(1):0.
[8]苟廷坤,赵婧,汤蓓,等.产前超声对胎儿前脑无裂畸形的诊断价值[J].中国计划生育和妇产科,2011,(02):0.
　GOU Ting-kun,ZHAO Jing,TANG Bei,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(1):0.
[9]谢伟,檀大羡,张海英,等.附睾囊肿诊断及对梗阻性无精子症的诊断价值[J].中国计划生育和妇产科,2011,(03):0.
　XIE Wei,TAN Da-xian,ZHANG Hai-ying..[J].Chinese Journal of Family Planning & Gynecotokology,2011,(1):0.
[10]刘杨,吴琼,侯莉,等.二、三维超声诊断宫内节育器异位的临床价值[J].中国计划生育和妇产科,2011,(03):0.
　LIU Yang,WU Qiong,HOU Li,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(1):0.

更新日期/Last Update: 2020-01-25